TNGX
What one share of Tango Therapeutics holds
Pharmaceutical Preparations
Tango Therapeutics was founded with a clear mission: to discover the next wave of targeted therapies in oncology by addressing the specific genetic alterations that drive cancer. We leverage our state-of-the-art target and drug discovery platforms to identify novel disease-relevant targets and develop medicines tailored to defined patient populations with high unmet medical need.
Tango Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.40 |
|---|---|
| Profit | −$0.91 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$1.07 |
| Cash and investments | $6.02 |
| Book value | $6.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.24 | −$1.63 | $0.03 | $2.16 | — | $0.96 |
| 2021 | $0.60 | −$0.94 | $0.03 | −$0.99 | — | $3.94 |
| 2022 | $0.28 | −$1.23 | $0.09 | −$1.33 | — | $2.83 |
| 2023 | $0.39 | −$1.08 | $0.02 | −$1.26 | — | $2.48 |
| 2024 | $0.39 | −$1.19 | $0.01 | −$1.21 | — | $1.85 |
| 2025 | $0.54 | −$0.87 | $0.01 | −$1.20 | — | $2.55 |